Top

BMC Psychiatry

Published in:

Open Access 01-12-2014 | Research article

Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials

Authors: Diarmid Sinclair, Clive E Adams

Published in: BMC Psychiatry | Issue 1/2014

Abstract

Background

Schizophrenia is a common serious mental health condition which has significant morbidity and financial consequences. The mainstay of treatment has been antipsychotic medication but one third of people will have a 'treatment resistant' and most disabling and costly illness. The aim of this survey was to produce a broad overview of available randomised evidence for interventions for people whose schizophrenic illness has been designated 'treatment resistant'.

Method

We searched the Cochrane Schizophrenia Group's comprehensive Trials Register, selected all relevant randomised trials and, taking care not to double count, extracted the number of people randomised within each study. Finally we sought relevant reviews on the Cochrane Library and investigated how data on this subgroup of people had been presented.

Results

We identified 542 relevant papers based on 268 trials (Average size 64.8 SD 61.6, range 7-526, median 56 IQR 47.3, mode 60). The most studied intervention is clozapine with 82 studies (total n = 6299) comparing it against other anti-psychotic medications. Cognitive behavioural therapy (CBT), electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) supplementing a standard care and risperidone supplementation of clozapine has also been extensively evaluated within trials. Many approaches, however, were clearly under researched. There were only four studies investigating combinations of non-clozapine antipsychotics. Only two psychological approaches (CBT and Family Rehabilitation Training) had more than two studies. Cochrane reviews rarely presented data specific to this important clinical sub-group.

Conclusions

This survey provides a broad taxonomy of how much evaluative research has been carried out investigating interventions for people with treatment resistant schizophrenia. Over 280 trials have been undertaken but, with a few exceptions, most treatment approaches - and some in common use - have only one or two relevant but small trials. Too infrequently the leading reviews fail to highlight the paucity of evidence in this area - as these reviews are maintained this shortcoming should be addressed.

Available only for authorised users

Sartorius N, Shapiro R, Kimura M, Barrett K: WHO international pilot study of schizophrenia. Psychol Med. 1972, 2 (4): 422-425. 10.1017/S0033291700045244.CrossRefPubMed

Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W: Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001, 178: 506-517. 10.1192/bjp.178.6.506.CrossRefPubMed

Meltzer HY: Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997, 14 (1): 1-20. 10.1185/03007999709113338.CrossRefPubMed

Mangalore R, Knapp M: Cost of schizophrenia in England. J Ment Health Policy Econ. 2007, 10 (1): 23-41.PubMed

Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC: Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res. 2011, 133 (1-3): 54-62. 10.1016/j.schres.2011.09.016.CrossRefPubMed

Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988, 45 (9): 789-796. 10.1001/archpsyc.1988.01800330013001.CrossRefPubMed

Conley RR, Buchanan RW: Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997, 23 (4): 663-674. 10.1093/schbul/23.4.663.CrossRefPubMed

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006, 163: 600-610. 10.1176/appi.ajp.163.4.600.CrossRefPubMed

Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006, 32 (4): 715-723. 10.1093/schbul/sbj067.CrossRefPubMedPubMedCentral

10.

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU: Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012, 138 (1): 18-28. 10.1016/j.schres.2012.03.018.CrossRefPubMedPubMedCentral

11.

Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D: Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012, 201 (6): 481-485. 10.1192/bjp.bp.111.105833.CrossRefPubMed

12.

Meltzer HY: Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 1992, 18 (3): 515-542. 10.1093/schbul/18.3.515.CrossRefPubMed

13.

Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, Ioannidis JP: Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol. 2004, 57 (11): 1124-1130. 10.1016/j.jclinepi.2004.02.018.CrossRefPubMed

14.

Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ: GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol. 2011, 64 (12): 1283-1293. 10.1016/j.jclinepi.2011.01.012.CrossRefPubMed

15.

Adams CE, Davis J, Duggan L, Essali A, Fenton M, Leucht S, Jayaram M, Li C, Tharyan P, Välimäki M, Cochrane Schizophrenia Group: About the Cochrane collaboration (Cochrane Review Groups (CRGs). Issue 8. Art. No.: SCHI.

16.

Jones C, Hacker D, Cormac I, Meaden A, Irving CB: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev. 2012, 4: CD008712-PubMedPubMedCentral

17.

Pharoah F, Mari Jair J, Rathbone J, Wong W: Family intervention for schizophrenia. Cochrane Database Syst Rev 2010, (12):Art. No.: CD000088. doi:10.1002/14651858.CD000088.pub3

18.

Rathbone J, Xia J: Acupuncture for schizophrenia. Cochrane Database Syst Rev 2005, (4):Art. No.: CD005475. doi:10.1002/14651858.CD005475

19.

Tharyan P, Adams Clive E: Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005, (2):Art. No.: CD000076. doi:10.1002/14651858.CD000076.pub2

20.

Dougall N, McIntosh A, Ebmeier Klaus P: Transcranial magnetic stimulation for schizophrenia. Cochrane Database Syst Rev 2006, (3):Art. No.: CD006081. doi:10.1002/14651858.CD006081.

21.

Cipriani A, Boso M, Barbui C: Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009, (3):Art. No.: CD006324. doi:10.1002/14651858.CD006324.pub2.

22.

Wang J, Omori Ichiro M, Fenton M, Soares Bernardo GO: Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev. 2010, (1): Art. No.: CD008125-doi:10.1002/14651858.CD008125.pub2

23.

Schwarz C, Volz A, Li C, Leucht S: Valproate for schizophrenia. Cochrane Database Syst Rev. 2008, (3): Art. No.: CD004028-doi:10.1002/14651858.CD004028.pub3

24.

Premkumar TS, Pick J: Lamotrigine for schizophrenia. Cochrane Database Syst Rev. 2006, (4): CD005962-doi:10.1002/14651858.CD005962.pub2

25.

Leucht S, Kissling W, McGrath J: Lithium for schizophrenia. Cochrane Database Syst Rev. 2007, (3): CD003834-doi:10.1002/14651858.CD003834.pub2

26.

Kour K, Kaur R, Singh J: Memantine for schizophrenia. Cochrane Database Syst Rev. 2013, (6): Art. No.: CD010552-doi:10.1002/14651858.CD010552

27.

Tiihonen J, Wahlbeck K: Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006, (2): Art. No.: CD003730-doi:10.1002/14651858.CD003730.pub2

28.

Leucht S, Helfer B, Dold M, Kissling W, McGrath J: Carbamazepine for schizophrenia. Cochrane Database Syst Rev. 2014, (5): Art. No.: CD001258-doi:10.1002/14651858.CD001258.pub3

29.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto Joaquim I, Kissling W, Leucht S: Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010, (1): Art. No.: CD006624-doi:10.1002/14651858.CD00624.pub2

30.

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh Hany G, Leucht S, Xia J: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014, (1): Art. No.: CD006569-doi:10.1002/14651858.CD006569.pub5

31.

Essali A, Al-Haj Haasan N, Li C, Rathbone J: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009, (1): Art. No.: CD000059-doi:10.1002/14651858.CD000059.pub2

32.

Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S: Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010, (11): Art. No.: CD006633-doi:10.1002/14651858.CD006633.pub2

33.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010, (3): Art. No.: CD006654-doi:10.1002/14651858.CD006654.pub2,

34.

Li C, Xia J, Wang J: Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009, (4): Art. No.: CD007474-doi:10.1002/14651858.CD007474.pub2

35.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S: Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011, (1): Art. No.: CD006626-doi:10.1002/14651858.CD006626.pub2

36.

Hunter R, Kennedy E, Song F, Gadon L, Irving Claire B: Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003, (2): Art. No.: CD000440-doi:10.1002/14651858.CD000440.

37.

Asmal L, Flegar Srnka J, Wang J, Rummel-Kluge C, Komossa K, Leucht S: Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013, (11): Art. No.: CD006625-doi:10.1002/14651858.CD006625.pub3

38.

Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmid F, Lewis R, Kissling W, Leucht S: Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009, (42): Art. No.: CD006752-doi:10.1002/14651858.CD006752.pub2

39.

Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi Paranthaman S, Kissling W, Leucht S: Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009, (4): Art. No.: CD006627-doi:10.1002/14651858.CD006627.pub2

40.

Saha Kumar B, Sampson S, Zaman Rashid U: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2013, (2): Art. No.: CD010631-doi:10.1002/14651858.CD010631

41.

Sampford J, Sampson S: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013, (11): Art. No.: CD010832-doi:10.1002/14651858.CD010832

42.

Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W: Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2011, (8): Art. No.: CD009230-doi:10.1002/14651858.CD009230.pub2

43.

Dold M, Li C, Tardy M, Leucht S: Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2012, (5): Art. No.: CD009831-doi:10.1002/14651858.CD009831

44.

Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W: Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2011, (10): Art. No.: CD009369-doi:10.1002/14651858.CD009369

45.

Lloyd K, White J: Democratizing clinical research. Nature. 2011, 474 (7351): 277-278. 10.1038/474277a.CrossRefPubMed

46.

Taylor DM, Smith L, Gee SH, Nielsen J: Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2012, 125 (1): 15-24. 10.1111/j.1600-0447.2011.01792.x.CrossRefPubMed

47.

Faries DA-SH, Zhu B, Correll C, Kane J: Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005, 5: 26-10.1186/1471-244X-5-26.CrossRefPubMedPubMedCentral

48.

Stahl SM: Emerging guidelines for the use of antipsychotic polypharmacy. Revista de psiquiatria y salud mental. 2013, 6 (3): 97-100.PubMed

49.

NICE: Psychosis and schizophrenia in adults: treatment and management. In NICE clinical guideline 178. Available at[www.nice.org.uk/CG178[NICE guideline].

50.

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004, 161 (2): 1-56.PubMed

51.

Kjaergard LL, Villumsen J, Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001, 135 (11): 982-989. 10.7326/0003-4819-135-11-200112040-00010.CrossRefPubMed

52.

Moher D, Dulberg CS, Wells GA: Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994, 272 (2): 122-124. 10.1001/jama.1994.03520020048013.CrossRefPubMed

53.

Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep. 1962, 10: 790-812.

54.

Leucht S, Kane JM, Kissling W, Hamann J, Etschel EVA, Engel R: Clinical implications of brief psychiatric rating scale scores. Br J Psychiatry. 2005, 187 (4): 366-371. 10.1192/bjp.187.4.366.CrossRefPubMed

Title: Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials
Authors: Diarmid Sinclair
Clive E Adams
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2014
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-014-0253-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials

Abstract

Background

Method

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Substance use in people at clinical high-risk for psychosis

Psychometric properties of a sign language version of the Mini International Neuropsychiatric Interview (MINI)

Social insecurity in relation to orbitofrontal activity in patients with eating disorders: a near-infrared spectroscopy study

Systematic review and meta-analysis of homicide recidivism and Schizophrenia

Gender differences in the association between adiposity and probable major depression: a cross-sectional study of 140,564 UK Biobank participants

Association between exposure to traumatic events and anxiety disorders in a post-conflict setting: a cross-sectional community study in South Sudan